Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Review Article

Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents

Author(s): Aysegul Hanikoglu, Ferhat Hanikoglu and Tomris Ozben*

Volume 19, Issue 3, 2018

Page: [333 - 340] Pages: 8

DOI: 10.2174/1389203718666170106101133

Price: $65

Abstract

Acetylation and deactylation of histones are important determinants of gene expression. Histone deacetylases (HDACs) remove acetyl groups from histones leading to suppression and regulation of epigenetic gene expression. Current studies have demonstrated that HDAC-inhibitors (HDACIs) inducing histone hyperacetylation are promising novel agents in cancer treatment. HDACIs have been shown to have significant anticancer effects with negligible toxicity in the preclinical studies. Ongoing clinial trials are being performed to investigate the efficiency of HDACIs in human cancers. We have reviewed the current knowledge about the molecular mechanisms of action of HDACIs and the outcome of clinical studies using HDACIs in the therapy of several cancers.

Keywords: Histone acetylation, histone deacetylase inhibitors, anticancer agents, epigenetic, hematologic malignancies, solid tumors.

« Previous
Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy